English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Significance Development of therapeutic strategies for Parkinson’s disease (PD) is hampered by the lack of reliable biomarkers to identify patients at early stages of the disease and track the therapeutic effect of potential drugs and neuroprotective agents. Readily accessible biomarkers capable of providing information about disease status are expected to accelerate this progress. We identified hepatocyte nuclear factor (HNF4A ) and polypyrimidine tract binding protein 1 (PTBP1 ) mRNAs as promising blood biomarkers for identifying early stage PD patients with high diagnostic accuracy. Furthermore,HNF4A was identified as a potential biomarker to monitor disease severity. Longitudinal analysis demonstrated thatHNF4A andPTBP1 are longitudinally dynamic biomarkers that provide insights into the molecular mechanisms underlying the altered insulin signaling in PD patients and may enable novel therapeutic strategies.

Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease